GB2483934A - Botanical extracts obtained by subcritical water extraction - Google Patents

Botanical extracts obtained by subcritical water extraction Download PDF

Info

Publication number
GB2483934A
GB2483934A GB1016229.5A GB201016229A GB2483934A GB 2483934 A GB2483934 A GB 2483934A GB 201016229 A GB201016229 A GB 201016229A GB 2483934 A GB2483934 A GB 2483934A
Authority
GB
United Kingdom
Prior art keywords
activity
skin
topical formulation
reducing
elastase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1016229.5A
Other versions
GB201016229D0 (en
Inventor
Gary William Wheatley
Kenneth Davison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB1016229.5A priority Critical patent/GB2483934A/en
Publication of GB201016229D0 publication Critical patent/GB201016229D0/en
Priority to GB201116833A priority patent/GB2484202B/en
Priority to GB201116834A priority patent/GB2484203B/en
Publication of GB2483934A publication Critical patent/GB2483934A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Abstract

Subcritical water extraction may be applied to botanical material (Baikal skullcap (Scutellaria baicalensis), St John's Wort (Hypericum perforatum), rosemary (Rosmarinus officinalis), lemon balm (Melissa officinalis), red clover (Trifolium pratense), Sophora flavescens, hawthorn (Crataegus spp.), Kudzu (Pueraria lobata), black cohosh (Cimicifuga species, especially varieties dahurica and racemosa), Paeonia species (especially varieties lactiflora and suffructicosa) or any closely related species) to give materials for use as anti-inflammatory agents and as agents for controlling the activity of matrix metalloproteinases typified by elastase and collagenase. The sub-critical water extraction may preferably be conducted at 150-200°C and/or at 70-85 bar. The extract may be incorporated into a topical formulation which may be suitable for reducing inflammation of the skin or for reducing the appearance of skin aging by reducing the activity of the proteolytic enzymes elastase and collagenase; it may be used as an adjunctive in the treatment of skin cancer.

Description

The Use of Botanical Extracts Produced by Sub-critical Water Extraction (SWE) as Anti-inflammatory and Skincare Agents.
FIELD OF THE INVENTION
The present invention relates to the use of certain botanical extracts produced by the evolving "(keen" technology of Sub-critical Water Extraction (SWE) as active ingredients in phannaceutical and healthcare applications. In particular the present invention relates to the use of the extracts as anti-inflammatory agents and in other skincare applications.
BACKGROUND TO THE INVENTION.
The appearance of the skin is critical to the self-esteem of an individual and can be adversely affected by a variety of factors including disease, injury, sunlight and age.
One of the most important anti-inflammatory mechanisms is the inhibition of eicosanoid generating enzymes [KIM et al, 2004].
Phospholipase A2 (PLA2) is a key enzyme in the early stages of the biosynthesis of pro-inflammatory mediators such as prostaglandins and leukotrienes. It is responsible for releasing the arachidonic acid precursor of these compounds from the phospholipids in which form it is stored [SIX & DENNIS, 2000].
Flavonoids and related polyphenols have been shown to be quite potent inhibitors of PLA2 activity [YOON & BACK, 2005].
Collagenase and elastase are examples of matrix metalloproteinases (MMPs) involved in the degradation of the extracellular matrix of the skin. Elevated activity of these enzymes, produced either by normal aging or exposure to excessive UV radiation, results in loss of skin tone and wrinkle formation [FISHER et al, 1997].
Inhibition of both elastase and coflagenase by plant extracts have previously been demonstrated and the activity generally correlated with the total polyphenolic content [THRING et al, 2009].
Flavonoids are thought to play a particularly important role [SIN&KIM, 2005; SIM et al, 2007].
A more recent approach to the production of extracts rich in polyphenolic compounds from botanical raw material is high pressure superheated water at >150°C, termed "sub-critical water". Sub-critical water has the unique property that the polarity of the solvent decreases in a predicable manner as temperature is increased; thus at 150°C the polarity of sub-critical water is equivalent to that of a 50:50 mixture of ethanol and water, and the polarity further decreases as the temperature is increased to 230°C to a value equivalent to that of pure methanol. A further advantage of sub-critical water extraction is that the high temperature and pressure produce high diffusion rates which promote very efficient extraction of the raw material.
Thus extracts rich in polyphenolic compounds produced as described above with demonstrable anti-inflammatory activity andlor inhibitory activity for important enzymes in dermal metabolism, such as collagenase and elastase, have clear applications as pharmaceuticals, skincare products and cosmaceuticals.
The recognition that inflammation processes are key to progression of cancer [GESCHER et al, 19981, combined with the fact that matrix metalloproteinases (as typified by collagenase and elastase) are implicated in the spread of a tumour through surrounding tissue and subsequent metastasis as a consequence of their activity in degrading the extracellular matrix [KANDASWAMI et al, 2005], imply that the extracts also have potential as adjunct treatments in the treatment of skin cancer.
This invention describes the anti-inflammatory activity and MMP inhibitory activity of a series of botanical extracts produced by Sub-critical Water Extraction that renders them useful as topical pharmaceutical and skincare agents.
Practical topical formulations of the extracts are also described, by reference to examples described in earlier patent filings by Advanced Extraction Technology Ltd [UK patent applications numbers 0817353.6, 0817354.4, 0910849.9, 0915193.7 & 0921581.5 & I 008305.3J which permit their use for the relief of the symptoms of inflammatory skin diseases and skin aging. Such topical fonnülations also exhibit promise as adjunctive treatments for skin cancer, combined with conventional chemotherapy and surgery, as a consequence of the anti-cancer actions and wound healing properties of many of the polyphenolic compounds which they contain.
LITERATURE CfltD: G.J.Fisber et al, New Eng.LMed.. fl, 1419 (1998).
A.Gescher et al, Br.J.CIin.Pharmacol., 45, 1-12 (1998).
C.Kandaswami et a!, In Vivo, j2; 895 (2005).
H.P.Kim et a!, J Pharmacol Sci, ., 229 (2004).
G.S.Sim et al, Arch Phartn Res, IQ, 290 (2007).
B.Y.Sin & H.P.Kinz Arch Phann Res, a 1152(2005).
D.A.Six & E.A.Dennis, Biochim.Biophvs.Acta. J.4$. 1 (2000).
T.S.A.Thring et a!, BMCCornp.AitMed.. 9-, 27(2009).
J-H Yoon & S.J.Back, Yonsei Med.J., 4 (5), 585 (2005).
UK Patent Application Number G1308 17353.6 TITLE: "A Method of Preparing Pharmacologically Active Extracts from Certain Medicinal Herbs in Traditional Use in Europe Without the Use of an Organic Solvent" (to Advanced Extraction Technology Ltd).
UK Patent Application Number GBO8 17354.4 TITLE: "A Method of Preparing Pharmacologically Active Extracts from Certain Medicinal Herbs in Traditional Use in Asia Without the Use of an Organic Solvent" (to Advanced Extraction Technology Ltd).
UK Patent Application Number GBO9 10949.9 TITLE: "Further Examples of Pharmacologically Active Extracts Prepared from Certain Medicinal Herbs in Traditional Use in Europe Without the Use of an Organic Solvent" (to Advanced Extraction Technology Ltd).
UK Patent Application Number (1130915193.7 TITLE: "The Production of a Flavonoid Enriched Fraction Prepared from Certain Skullcap Species Using Sub-critical Water Extraction." (to Advanced Extraction Technology Ltd).
UK Patent Application Number 0B092 1581.5 TITLE: "Methods for the Production of Sub-critical Water Extracts of Certain Plants with Healthcare Applications" (to Advanced Extraction Technology Ltd).
UK Patent Application Number GB 1008305.3 TITLE: "An Improved Design of Sub-critical Water Extraction (SWE) Apparatus and Applications Utilising the Above" (to Advanced Extraction Technology Ltd).
SUMMARY OF ThE INVENTION.
The present invention was made in view of the prior art described above, and the object of the present invention is to provide new and effective anti-inflammatory agents and also agents for inhibiting the activity of matrix metalloproteinases typified by elastase and collagenase The invention describes the use of certain botanical extracts produced by Sub-critical Water Extraction (SWE) for the improvement of skin health by the reduction of inflammation and the control of elastase and collagenase activity.
Further, by reference to examples of topical formulations described in earlier patents filed by Advanced Extraction Technology Ltd. the means of treating a variety of skin disorders are included in the invention.
The scope of the invention is illustrated by the following series of examples, although not in any limitative sense.
Example 1:
The botanical extracts produced by SWE can be used to control inflammation by the inhibition of Phospholipase A2 (PLA2), and thus consequent production of pro-inflammatory mediators.
This is illustrated by the following data obtained from cell free enzyme inhibition studies: SWE Extract IC25 IC50 IC,5 Baikal skullcap flavonoids 0.01 0.03 0.04 Rosemary 0.03 0.05 0.14 Lemon Balm 0.14 0.24 * Red Clover 0.04 0.08 0.25 Sophora root 0.04 0.07 0.18 Hypericum 0.03 0.05 0.08 Hawthorn 0.04 0.07 0.16 Kudzu root 0.04 0.07 * Black Cohosh 0.04 0.10 * Peonyroot 0.06 0.11 * * not quantifiable due to problems of solubility of the test article in the assay medium.
IC refers to the concentration required to produce n% inhibition of the activity of the enzyme, and concentrations are quoted in mg/mi.
As can be seen, the Baikal skullcap flavonoid fraction exhibits the strongest inhibitor with 75% inhibition of PLA2 activity being produced at a concentration of only 0.04 mgfml. Other notably active extracts included those of Hypericum, rosemary, sophora root, hawthorn and Kudzu root.
Example 2.
The botanical extracts produced by SWE can be used to inhibit excessive activity of the proteolytic enzyme elastase which results in tissue damage or aging. This is illustrated by the following data obtained from cell free enzyme inhibition studies: The SWE extract of Hypencumperforatum was found to produce 25%, 50% & 75% inhibition of elastase activity at concentrations of 0. 16, 0.29 & 0.43 mg/mI respectively.
This inhbition was greater than that produced by the established elastase inhibitor utitised as a positive control in the assays.
The flavonoid fraction of Baikal skullcap produced by SWE was found to exhibit comparable activity with 25% inhibition being produced at 0.15 mg/mi Other SWE extracts (including those produced from rosemary, sophora, hawthorn and Kudzu) exhibited some inhibition of this enzyme but were less potent than the above examples.
Example 3.
The botanical extracts produced by SWE can be used to inhibit excessive activity of the proteolytic enzyme elastase which results in tissue damage or aging. This is illustrated by the following data obtained from cell free enzyme inhibition studies: The SWE extract ofHypericumpeifora:um was found to produce 25%, 50% & 75% inhibition of collagenase activity at concentrations of 0.09, 0.29 & 0.49 mg/mi respectively. This inhibition was stronger than that produced by the established elastase inhibitor utilised as a positive control in the assays.
The flavonoid fraction ofBaikal skullcap produced by SWE, the sophora extract and the Kudzu extract were found to exhibit slightly weaker activity with 25% inhibition being produced at 0.15, 0.15 & 0.17 mg/mI respectively Other SWE extracts (including those produced red clover, hawthorn and peony root) exhibited some inhibition of this enzyme but were less potent than the above examples.
Example 4.
As a consequence of the anti-inflammatory activity and MM? inhibitory activity described in Examples 1-3 the extracts, in particular the flavonoid fraction of Baikal skullcap and the extract ofHypericurnperforatum which exhibit &eatest activity, may be applied as a suitable topical formulation as an adjunctive treatment to supplement surgical or chemotherapeutic intervention in skin cancer.
Example 5.
The above extracts described in previous examples can be incorporated into a topical formulation described in the UK patent applications numbers 0817353.6, 0817354.4, 0910849.9, 0915193.7, 0921581.5 & 1008305.3 previously filed by Advanced Extraction Technology Ltd. This then permits the use of the extracts as topical pharmaceuticals and skincare products.
While the preferred embodiments of the invention have been described above, it will be recognised and understood by those skilled in the art that various modifications may be made therein, and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention.

Claims (10)

  1. CLAIMS1. The use of certain botanical extracts, prepared by the technique of Sub-critical Water Extraction, as anti-inflammatoiy agents and as agents for controlling the activity of matrix metalloproteinases typified by elastase and collagenase.
  2. 2. The method according to claim 1 wherein the extracts are prepared using the technique of Sub-critical Water Extraction as described in UK patent application numbers 0817353.6, 0817354.4, 0910849.9, 0915193.7, 0921581.5 & 1008305.3.
  3. 3. The method according to any preceding claim wherein the extraction is carried out at a temperature in the range 150-230°C, and most preferably in the range in the range 150-200°C as described in UK patent application numbers 0817353.6, 0817354.4, 0910849.9, 0915193.7, 0921581.5 & 1008305.3.
  4. 4. The method according to any preceding claim wherein the extraction is carried out at a pressure in the range 15-100 bar sufficient to maintain the water in the liquid phase, and most preferably at 70-85 bar as described in UK patent application numbers 0817353.6, 0817354.4, 0910849,9, 0915193.7, 0921581.5 & 1008305.3.
  5. 5. The method according to any preceding claim wherein the extract is selected from the group consisting of the traditionally used parts of Baikal skullcap (Scutellaria baicalensis), St John's Wort (Hypericum peforatum), rosemary (Rosmarinus offi c/nails), lemon balm (Melissa ofjicinaiis), Red clover (Trfolium pratense), Sophorafiavescens, hawthorn (Crataegus spp), Kudzu (Pueraria lobata), black cohosh (Ci,niqfuga species, especially varieties dahurica and racemosa), Paeonia species (especially varieties lactijiora and suJfructicosa), and also including species closely related to any of the foregoing.
  6. 6. The method according to claims 1-5 wherein the extract is incorporated into a topical formulation selected from those previously described in UK patent application numbers 0817353.6, 0817354.4, 0910849.9, 0915193.7, 0921581.5 & 1008305.3, previously filed by Advanced Extraction Technology Ltd.
  7. 7. The use of a topical formulation as claimed in any of the preceding claims as an agent for reducing inflammation of the skin.
  8. 8. The use of a topical formulation as claimed in any of the preceding claims as an agent for reducing the appearance of skin aging by reducing the activity of the proteolytic enzymes elastase and collagenase.
  9. 9. The use of a topical formulation as claimed in any of the preceding claims as an adjunctive treatment in the treatment of skin cancer.
  10. 10. The use of a topical formulation as claimed in any preceding claim wherein the active substance comprises a more refined fraction derived from the described total extracts of the botanical raw materials.
GB1016229.5A 2010-09-27 2010-09-27 Botanical extracts obtained by subcritical water extraction Withdrawn GB2483934A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB1016229.5A GB2483934A (en) 2010-09-27 2010-09-27 Botanical extracts obtained by subcritical water extraction
GB201116833A GB2484202B (en) 2010-09-27 2011-09-29 Detector responsive to interactions of varying intensity
GB201116834A GB2484203B (en) 2010-09-27 2011-09-29 Resistance changing sensor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1016229.5A GB2483934A (en) 2010-09-27 2010-09-27 Botanical extracts obtained by subcritical water extraction

Publications (2)

Publication Number Publication Date
GB201016229D0 GB201016229D0 (en) 2010-11-10
GB2483934A true GB2483934A (en) 2012-03-28

Family

ID=43128035

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1016229.5A Withdrawn GB2483934A (en) 2010-09-27 2010-09-27 Botanical extracts obtained by subcritical water extraction

Country Status (1)

Country Link
GB (1) GB2483934A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150110907A1 (en) * 2002-11-19 2015-04-23 Basf Beauty Care Solutions France S.A.S. Method of testing the activity of a potentially active substance to inhibit the enzymatic activity of phospholipase a2
CN108852929A (en) * 2018-07-10 2018-11-23 珀莱雅化妆品股份有限公司 A kind of preparation method with the guava leaf extract of antiallergic

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11147833A (en) * 1997-11-18 1999-06-02 Noevir Co Ltd Collagenase inhibitor
JPH11263720A (en) * 1998-03-13 1999-09-28 Shiseido Co Ltd Antiaging agent
US20050008717A1 (en) * 2002-12-27 2005-01-13 Einbond Linda Saxe Anti-neoplastic compositions comprising extracts of black cohosh
US20050226943A1 (en) * 2004-04-01 2005-10-13 Xiaoqiang Yan Extract of sophora flavescens flavonoids and uses thereof
CN101375954A (en) * 2007-08-27 2009-03-04 天津药物研究院 Medicament composition, preparation method thereof and use
KR20090128230A (en) * 2008-06-10 2009-12-15 (주)아모레퍼시픽 Cosmetic composition containing scutellaria baicalensis extract using processing of herbal medicine
WO2010034971A2 (en) * 2008-09-23 2010-04-01 Gary William Wheatley Sub-critical water extraction of medicinal plants
GB2471293A (en) * 2009-06-24 2010-12-29 Kenneth Davison The extraction of pharmacological agents from medicinal herbs using subcritical water
KR20110038548A (en) * 2009-10-08 2011-04-14 청운대학교산학협력단 Composition containing black cohosh extract for anti-irritation effect
GB2476070A (en) * 2009-12-10 2011-06-15 Kenneth Davison Subcritical water extraction of Hawthorn Crategus monogyna, Pueraria lobata and Centella asiatica

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11147833A (en) * 1997-11-18 1999-06-02 Noevir Co Ltd Collagenase inhibitor
JPH11263720A (en) * 1998-03-13 1999-09-28 Shiseido Co Ltd Antiaging agent
US20050008717A1 (en) * 2002-12-27 2005-01-13 Einbond Linda Saxe Anti-neoplastic compositions comprising extracts of black cohosh
US20050226943A1 (en) * 2004-04-01 2005-10-13 Xiaoqiang Yan Extract of sophora flavescens flavonoids and uses thereof
CN101375954A (en) * 2007-08-27 2009-03-04 天津药物研究院 Medicament composition, preparation method thereof and use
KR20090128230A (en) * 2008-06-10 2009-12-15 (주)아모레퍼시픽 Cosmetic composition containing scutellaria baicalensis extract using processing of herbal medicine
WO2010034971A2 (en) * 2008-09-23 2010-04-01 Gary William Wheatley Sub-critical water extraction of medicinal plants
GB2471293A (en) * 2009-06-24 2010-12-29 Kenneth Davison The extraction of pharmacological agents from medicinal herbs using subcritical water
KR20110038548A (en) * 2009-10-08 2011-04-14 청운대학교산학협력단 Composition containing black cohosh extract for anti-irritation effect
GB2476070A (en) * 2009-12-10 2011-06-15 Kenneth Davison Subcritical water extraction of Hawthorn Crategus monogyna, Pueraria lobata and Centella asiatica

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WPI abstract accession no 2009-S68982 [04] & KR 20090128230 A (AMOREPACIFIC CORP) *
WPI abstract accession no 2011-E19138 [36] & KR 20110038548 A (IND ACADEMIC COOP) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150110907A1 (en) * 2002-11-19 2015-04-23 Basf Beauty Care Solutions France S.A.S. Method of testing the activity of a potentially active substance to inhibit the enzymatic activity of phospholipase a2
CN108852929A (en) * 2018-07-10 2018-11-23 珀莱雅化妆品股份有限公司 A kind of preparation method with the guava leaf extract of antiallergic
CN108852929B (en) * 2018-07-10 2021-05-04 珀莱雅化妆品股份有限公司 Preparation method of guava leaf extract with anti-allergy effect

Also Published As

Publication number Publication date
GB201016229D0 (en) 2010-11-10

Similar Documents

Publication Publication Date Title
Li et al. HPLC fingerprint analysis of Phyllanthus emblica ethanol extract and their antioxidant and anti-inflammatory properties
Lall et al. Are plants used for skin care in South Africa fully explored?
JP5893135B2 (en) Combinations of active substances that induce the synergistic effect of multiple targeting and their uses
Lin et al. Antioxidant, antioedema and analgesic activities of Andrographis paniculata extracts and their active constituent andrographolide
RU2358750C2 (en) Pharmaceutical compositions based on barbate lichen (usnea barbata) and common st john's wort (hypericum perforatum) and application thereof
JP2017193560A (en) Sebum production-inhibiting composition comprising saururus chinensis extract
CN106265977B (en) Peony seed extract, preparation method and application thereof, and skin external preparation comprising peony seed extract
Yao et al. Different harvest seasons modify bioactive compounds and antioxidant activities of Pyrola incarnata
Kanlayavattanakul et al. Phenolic-rich pomegranate peel extract: in vitro, cellular, and in vivo activities for skin hyperpigmentation treatment
Akkol et al. In vitro enzyme inhibitory effects of Rubus sanctus Schreber and its active metabolite as a function of wound healing activity
Zengin et al. Preliminary investigation on chemical composition and bioactivity of differently obtained extracts from Symphytum aintabicum Hub.-Mor. &Wickens
Zhu et al. Evaluation of whitening and antimicrobial activity of two strains of Bletilla striata WT and HL20
GB2483934A (en) Botanical extracts obtained by subcritical water extraction
BRPI0914462B1 (en) TOPIC COMPOSITION
Miraj et al. Evaluation of the analgesic and anti-inflammatory activities of methanolic extracts of the leaves of Averrhoa bilimbi leaves
CN111419940B (en) Chinese herbal medicine composition for removing acne
Saqib et al. In vitro inhibitory potential of methanolic extract of Celosia argentea var. cristata on tyrosinase, acetylcholinesterase and butyrylcholinesterase enzymes
Yoon et al. Skin whitening effect of Sedum kamtschaticum fisch. solvent fractions
Pandey et al. Enhanced anti-ageing and wound healing properties of Ficus religiosa L. bark, leaf and aerial root extract in human keratinocytes cell line (HaCaT)
KR20130090071A (en) Selective extracted method for acne-prone skin antibacterial ingredient using supercuritical fluid from ginger
EP2788011B1 (en) Composition comprising a chelidonium majus extract and copaiba, and the use thereof for the treatment of cutaneous dysfunctions
Ferrara Cardiospermum halicacabum Linn.: food and drug
KR20120081289A (en) A skin-care agent containing fermented licorice extracts
CN106619289B (en) Acne-removing anti-sensitivity moisturizing composition containing frangipani alcohol extract and preparation method thereof
CN102887924A (en) Preparation of active components for tyrosinase inhibition from agricultural and forestry waste walnut shell and application of active components

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)